ImageneBio, Inc.(IMA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

ImageneBio, Inc. (IMA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMA at 6.6/100 on a 32-signal composite quality model, placing it at rank #2,951 of 2,961 stocks — the bottom half of the AI-ranked universe. IMA scores in the top quartile across institutional flow (87.6). Areas of concern include revenue scale (0.2) and free cash flow (0.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.4/100, reflecting ongoing share issuance or stock-based compensation. Top institutional holders of IMA by reported 13-F value include BVF, Blue Owl Capital, ORBIMED ADVISORS, based on the most recent SEC filings. IMA trades on the Nasdaq exchange and files with the SEC under CIK 1835579. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ImageneBio, Inc. directly from SEC EDGAR.